Phase 2 Clinical Trial Progress Update

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

25 March 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Phase 2 Clinical Trial Progress Update

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, provides a progress update on its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma.   

The Company confirms that its US-based contract development and manufacturing organisation, ProMed Pharma LLC, has successfully manufactured the first clinical batch of ChemoSeed in accordance with current Good Manufacturing Practice standards. The batch will now undergo sterilisation and release testing, making it ready for use in the Phase 2 trial.

The Company also continues to work closely with its contract research organisation, Aixial, and the first clinical trial site, to complete the remaining site activation steps so as to commence patient dosing. Although progress toward trial commencement is moving at pace, the exact timing of first patient dosing is difficult to anticipate. As such, the Company is extending guidance on the timing of first patient dosing to H1 2026. The Company remains focused on initiating the trial shortly and will provide further updates on the commencement of the trial as soon as possible.

-Ends-

Enquiries:

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.